Abstract
Introduction: Hidradenitis suppurativa is a chronic skin disease with a significant unmet need for treatment options. Randomized controlled trials are few and only a single drug (adalimumab) has Hidradenitis as a registered indication. Areas covered: The clinicaltrials.gov and the EudraCT clinical trials register for reported trials on Hidradenitis Suppurativa was searched on the 22–06-2017. Trials for upcoming new drugs for HS are reported focusing on drugs in phase I and II trials. Expert opinion: Currently, MABp1, Secukinumab, CJM112, Apremilast and IFX-1 are being investigated in Phase I and II trials and offer theoretical and promising new treatment options. A trial with the drug MEDI8968 has been terminated with disappointing results. Metformin, Botulinum Toxin B, Provodine, Benzoyl Peroxide and intralesional triamcinolone are being tested as well. Treatment of Hidradenitis remains a challenge and quality RTCs are needed. Studies indicates a range of potential targets for therapy such as interleukin-1 and interleukin-17, but ‘broad-spectrum’ immunosuppressants like phosphodiesterase-4 inhibitors are being examined as well. A range of outcomes, including Physician Global Assessment, Sartorius scores and hidradenitis suppurativa clinical response are used in these trials, making future meta-analysis of the data difficult.
| Original language | English |
|---|---|
| Journal | Expert Opinion on Investigational Drugs |
| Volume | 27 |
| Issue number | 1 |
| Pages (from-to) | 43-53 |
| Number of pages | 11 |
| ISSN | 1354-3784 |
| DOIs | |
| Publication status | Published - 2018 |
Keywords
- Acne Inversa
- Apremilast
- CJM112
- Hidradenitis Suppurativa
- IFX- 1
- MABp1
- MEDI8968
- Secukinumab